ClearNote Health

📢 Don't miss our poster presentation at #ASCO25 Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of cancer mortality, with ~33% of patients developing metastases and a poor 5-year survival rate of ~15%. While surgical resection offers a potential cure for a subset of metastatic CRC (mCRC) patients, tools to predict post-surgical outcomes remain inadequate. There is a critical need for non-invasive biomarkers that can guide treatment decisions and identify patients likely to benefit from curative surgery. Join our Senior Scientist for Translational Research, Ceyda Coruh, on May 31 (9:00 AM – 12:00 PM) for a poster presentation on how 5-hydroxymethylcytosine (5hmC) of cell-free DNA (cfDNA) offers a novel, non-invasive approach for identification of colorectal cancer biology and assessment of treatment response in blood samples. 🤝 Reach out directly to Ceyda to schedule a meeting at the event. #Epigenetics #cfDNA #Biomarkers #ColorectalCancer #PrecisionOncology #5hmC #ASCO2025

Early cancer detection saves lives but today, routine testing is only available for a handful of cancer types.   In a recently published article in Diagnostics World, our CEO Dave Mullarkey shares how a stepping-stone approach, starting with single-cancer tests targeting high-mortality cancers, can lay the groundwork for broad, multi-cancer early detection.   “Ultimately, the long-term vision is to get to early detection of multiple cancers with a single test. But we’ll need to embrace incremental change to get there. When we do finally achieve this vision, physicians and patients alike will be empowered not only with the right early detection tools but also with the mindset that this approach will give them the best chance at having long, healthy lives.’’   👉  Read the full article here: https://lnkd.in/dzDPTQrk   #CancerDetection #PrecisionMedicine #MultiCancerDetection

📢 Press Release: Human Longevity, Inc., Expands Cancer Prevention Offering by Selecting the ClearNote Health Avantect® Early Detection Pancreatic Cancer Test ''We are proud to join forces with Human Longevity to deliver the Avantect test to clients who are deeply invested in proactive health management. By integrating our epigenomic innovation with HLI's world-class genomic and imaging capabilities, we are redefining what is possible in early #pancreaticcancer detection - and giving individuals a greater opportunity to change their future.'' comments Dave Mullarkey, CEO of ClearNote Health. 👉 Read the full press release: https://lnkd.in/dEktbczi

Meet Our Chief Scientific Officer, Dr. Samuel Levy, at Digestive Disease Week® (DDW) 2025! Dr. Levy is a recognized leader in genomics and early cancer detection, bringing decades of experience translating cutting-edge science into transformative diagnostic solutions. Speak with Dr. Levy at our booth to learn how ClearNote Health is harnessing the power of the epigenome to drive early pancreatic cancer detection and transform patient outcomes. 📍 Location: Booth 5525 📅 When: May 4th & 5th, 12:00-2:00pm #pancreaticancer #earlydetection

📢 Join ClearNote Health at Digestive Disease Week® (DDW) in San Diego, May 4-6, where we’ll be showcasing the Avantect® Pancreatic Cancer Test - a groundbreaking epigenomic liquid biopsy designed to aid in the early detection of pancreatic cancer.   📍 Early detection can make all the difference. Visit us at booth #5525 to learn how Avantect’s innovative 5hmC-based technology is transforming patient care with a simple blood test that brings new hope to those at high risk.   Let’s advance early detection together. #DDW2025 #PancreaticCancer #EarlyDetection #Epigenomics

Last week, we proudly celebrated National Medical Laboratory Professionals Week at ClearNote Health! 🎉 A huge thank you to our tremendous laboratory team for their on-going commitment and dedication to our mission of saving lives through earlier detection of cancer. Your work is so essential, and we are very fortunate to have the talented laboratory team we have at ClearNote Health. We had a blast with our Lab Olympics events - from Glove Launch to Lab Pong, Bingo, Guess the Baby Lab Tech, and Timed PPE! 🧤🏓 😀 We’ll be wrapping up with a closing ceremony soon, where we'll award prizes and medals to our top competitors. 🥇🥈🥉 #LabWeek #ThankYouLabProfessionals

ClearNote Health will be showcasing the latest advancements in tumor subtyping and circulating tumor fraction technologies at the American Association for Cancer Research Annual Meeting 2025. “ClearNote Health is looking forward to updating the AACR community about the significant progress we’ve made in empowering drug development through epigenomics,” said Gulfem D. Guler. PhD, Vice President of Translational Research and Head of Biopharma Development at ClearNote Health. “Our proprietary Virtuoso™ epigenomics platform measures active disease biology and provides dynamic insights into drug response and resistance, all through a simple blood draw.” 👉 Learn more about Virtuoso or read about the presentations here: https://lnkd.in/dHPbBsib #epigenomics #drugdevelopment

📢 Our team will be out in full force at the American Association for Cancer Research Annual Meeting 2025, April 25-30, 2025, taking place at the McCormick Place Convention Center, Chicago, Illinois. Discover how our Virtuoso Epigenomics Platform is empowering more efficient oncology drug discovery and development by leveraging 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma. Don't miss our poster presentation and collaborator poster presentation to learn more: 🗒️ Title: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and identifies loss of AR signaling in NEPC and DNPC Presenting author: Rensheng Wan (UCSF) Session Title: Liquid Biopsy: Circulating Tumor Cells 1 Session Start: 4/28/2025 9:00:00 AM Session End: 4/28/2025 12:00:00 PM Location: Poster Section 29 Poster Board Number: 20 Published Abstract Number: 1985   🗒️ Title: A tumor-naïve method for estimating tumor fraction using 5-hydroxymethylation cytosine in cell–free DNA Presenting author: Ceyda Coruh (ClearNote Health) Session Title: Convergence Science Diagnostic and Predictive Approaches Session Date and Time: Monday Apr 28, 2025 2:00 PM – 5:00 PM Location: Poster Section 46 Poster Board Number: 10 Published Abstract Number: 3681 👉 Reach out to schedule a meeting: [email protected] #LiquidBiopsy #Cancer #Epigenomics #Oncology

ClearNote Health is now on Bluesky Social. Follow our account to stay updated on all our latest news: 🦋 https://lnkd.in/dvRUtunk #cancerdetection #pancreaticcancer #epigenomics

Great article in The Guardian over the weekend on a recent large-scale UK Biobank study on how type 2 diabetes can increase risk of liver and pancreatic cancer. The study analyzed health records from  23,750 people with newly diagnosed type 2 diabetes and compared them with more than 70,000 matched controls without diabetes. Researchers found that the risk of pancreatic cancer was nearly twice as high in women and 74% higher in men for those recently diagnosed with the condition.    ⚠️ Early detection is key. The ClearNote Avantect test is a simple cell-free DNA-based blood test that is designed to detect the earliest indicators of pancreatic cancer when patients are most likely to benefit from treatment.   Read the article https://lnkd.in/ddr2HJpM and learn more about the Avantect test on our website: https://www.avantect.com/   #pancreaticcancer #earlydetection